Panelists discuss how patient portal use improves communication by allowing patients to report adverse effects with photos ...

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value ...

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during ...

Based on durable response data, TAR-200 has been given priority review for the treatment of patients with high-risk ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of ...